Adia Nutrition Reports Revenue Surge to $661,660 and Net Income Recovery in Latest Filing

Adia Nutrition, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenues reaching $661,660 for the six months ended June 30, 2026, compared to $189,910 for the same period in 2025. The company generated a net income of $40,418 for the three months ended June 30, 2026, a notable recovery from a net loss of $123,997 in the prior year. The increase in revenue was primarily driven by a substantial rise in medical procedures, which accounted for $434,670, up from $96,700 in the previous year, and sales of biologics, which rose to $221,525 from $87,500.

The financial results reflect a marked improvement in gross profit, which increased to $350,157 for the six months ended June 30, 2026, compared to $39,975 in the same period last year. This growth was accompanied by a rise in operating expenses, which totaled $450,248, up from $267,105 in the prior year. The increase in expenses was attributed to higher legal and professional fees, clinical trial costs, and advertising expenditures, indicating the company's investment in growth and operational capabilities.

Adia Nutrition has also made strategic moves to enhance its market position, including the acquisition of Biolete, LLC, which was completed in July 2024. This acquisition, valued at $72,000, was aimed at expanding the company's product offerings in the health and wellness sector. Additionally, the company has taken an 18% equity position in Cement Factory, LLC, further diversifying its investment portfolio. The company’s operational focus has shifted towards providing Autologous Hematopoietic Stem Cell Transplantation (AHSCT) treatments for Multiple Sclerosis patients, indicating a commitment to innovative healthcare solutions.

Operationally, Adia Nutrition has seen a significant increase in its customer base and engagement metrics, particularly in its medical procedures segment. The company reported a total of 94,404,696 Class A common shares outstanding as of June 30, 2026, with a total asset value of $744,054, up from $594,826 at the end of 2025. However, the company continues to face challenges, including an accumulated deficit of $16,095,589, raising concerns about its ability to sustain operations without additional capital. Management has indicated plans to leverage its line of credit and seek further funding to support ongoing growth initiatives.

Looking ahead, Adia Nutrition anticipates continued revenue growth and aims to maintain operational efficiency. The company plans to focus on enhancing its healthcare offerings and expanding its market reach while managing costs effectively. However, the outlook remains cautious, as the company acknowledges the need for increased revenues and capital to ensure its long-term viability.